Data from the Phase 1 clinical trial of novel KCNK13 inhibitor showed good CNS exposure and was generally ...

CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced it will deliver Developing Topics (late-breaking) virtual ...